vs

Side-by-side financial comparison of GENCO SHIPPING & TRADING LTD (GNK) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $114.4M, roughly 1.3× GENCO SHIPPING & TRADING LTD). GENCO SHIPPING & TRADING LTD runs the higher net margin — 8.4% vs -5.5%, a 13.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 60.6%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 3.4%).

Genco Shipping & Trading Ltd is a global dry bulk shipping enterprise that operates a diversified fleet of bulk carriers, transporting essential commodities including iron ore, coal, grain, and steel products across major international trade routes, serving industrial, manufacturing, and commodity trading clients worldwide.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

GNK vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$114.4M
GNK
Growing faster (revenue YoY)
TARS
TARS
+67.8% gap
TARS
128.4%
60.6%
GNK
Higher net margin
GNK
GNK
13.9% more per $
GNK
8.4%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
3.4%
GNK

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
GNK
GNK
TARS
TARS
Revenue
$114.4M
$151.7M
Net Profit
$9.6M
$-8.4M
Gross Margin
Operating Margin
11.6%
-5.3%
Net Margin
8.4%
-5.5%
Revenue YoY
60.6%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.21
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GNK
GNK
TARS
TARS
Q1 26
$114.4M
Q4 25
$109.9M
$151.7M
Q3 25
$79.9M
$118.7M
Q2 25
$80.9M
$102.7M
Q1 25
$71.3M
$78.3M
Q4 24
$99.2M
$66.4M
Q3 24
$99.3M
$48.1M
Q2 24
$107.0M
$40.8M
Net Profit
GNK
GNK
TARS
TARS
Q1 26
$9.6M
Q4 25
$15.4M
$-8.4M
Q3 25
$-1.1M
$-12.6M
Q2 25
$-6.8M
$-20.3M
Q1 25
$-11.9M
$-25.1M
Q4 24
$12.7M
$-23.1M
Q3 24
$21.5M
$-23.4M
Q2 24
$23.5M
$-33.3M
Operating Margin
GNK
GNK
TARS
TARS
Q1 26
11.6%
Q4 25
17.3%
-5.3%
Q3 25
3.1%
-12.2%
Q2 25
-5.3%
-21.6%
Q1 25
-13.7%
-33.5%
Q4 24
14.7%
-36.8%
Q3 24
24.2%
-52.3%
Q2 24
24.6%
-81.6%
Net Margin
GNK
GNK
TARS
TARS
Q1 26
8.4%
Q4 25
14.0%
-5.5%
Q3 25
-1.3%
-10.6%
Q2 25
-8.4%
-19.8%
Q1 25
-16.7%
-32.1%
Q4 24
12.8%
-34.8%
Q3 24
21.6%
-48.7%
Q2 24
21.9%
-81.6%
EPS (diluted)
GNK
GNK
TARS
TARS
Q1 26
$0.21
Q4 25
$0.36
$-0.17
Q3 25
$-0.02
$-0.30
Q2 25
$-0.16
$-0.48
Q1 25
$-0.28
$-0.64
Q4 24
$0.29
$-0.57
Q3 24
$0.49
$-0.61
Q2 24
$0.54
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GNK
GNK
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$54.8M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$887.0M
$343.4M
Total Assets
$1.3B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GNK
GNK
TARS
TARS
Q1 26
$54.8M
Q4 25
$55.5M
$417.3M
Q3 25
$90.0M
$401.8M
Q2 25
$35.4M
$381.1M
Q1 25
$30.2M
$407.9M
Q4 24
$43.7M
$291.4M
Q3 24
$46.7M
$317.0M
Q2 24
$42.0M
$323.6M
Total Debt
GNK
GNK
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
GNK
GNK
TARS
TARS
Q1 26
$887.0M
Q4 25
$896.5M
$343.4M
Q3 25
$885.9M
$335.1M
Q2 25
$891.6M
$332.6M
Q1 25
$903.2M
$342.5M
Q4 24
$926.7M
$224.5M
Q3 24
$929.9M
$237.5M
Q2 24
$921.8M
$252.2M
Total Assets
GNK
GNK
TARS
TARS
Q1 26
$1.3B
Q4 25
$1.1B
$562.2M
Q3 25
$1.1B
$534.6M
Q2 25
$1.0B
$495.0M
Q1 25
$1.0B
$500.8M
Q4 24
$1.1B
$377.0M
Q3 24
$1.0B
$376.3M
Q2 24
$1.1B
$376.8M
Debt / Equity
GNK
GNK
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GNK
GNK
TARS
TARS
Operating Cash FlowLast quarter
$15.7M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
1.64×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GNK
GNK
TARS
TARS
Q1 26
$15.7M
Q4 25
$15.9M
$19.3M
Q3 25
$7.7M
$18.3M
Q2 25
$5.4M
$-29.4M
Q1 25
$2.9M
$-20.7M
Q4 24
$30.0M
$-22.2M
Q3 24
$35.6M
$-8.7M
Q2 24
$29.0M
$-14.4M
Free Cash Flow
GNK
GNK
TARS
TARS
Q1 26
Q4 25
$15.6M
$13.0M
Q3 25
$6.5M
$16.3M
Q2 25
$4.3M
$-30.4M
Q1 25
$2.3M
$-21.2M
Q4 24
$29.3M
$-22.3M
Q3 24
$34.7M
$-8.9M
Q2 24
$27.9M
$-15.4M
FCF Margin
GNK
GNK
TARS
TARS
Q1 26
Q4 25
14.2%
8.6%
Q3 25
8.2%
13.8%
Q2 25
5.3%
-29.6%
Q1 25
3.2%
-27.1%
Q4 24
29.5%
-33.5%
Q3 24
34.9%
-18.6%
Q2 24
26.1%
-37.8%
Capex Intensity
GNK
GNK
TARS
TARS
Q1 26
Q4 25
0.3%
4.2%
Q3 25
1.5%
1.6%
Q2 25
1.3%
1.0%
Q1 25
0.9%
0.8%
Q4 24
0.7%
0.1%
Q3 24
0.9%
0.6%
Q2 24
1.1%
2.5%
Cash Conversion
GNK
GNK
TARS
TARS
Q1 26
1.64×
Q4 25
1.03×
Q3 25
Q2 25
Q1 25
Q4 24
2.37×
Q3 24
1.66×
Q2 24
1.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons